Abbott Laboratories $ABT Shares Bought by SYM FINANCIAL Corp

SYM FINANCIAL Corp raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 110.1% during the second quarter, HoldingsChannel reports. The firm owned 8,189 shares of the healthcare product maker’s stock after purchasing an additional 4,292 shares during the quarter. SYM FINANCIAL Corp’s holdings in Abbott Laboratories were worth $743,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Brighton Jones LLC increased its position in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC grew its stake in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares during the last quarter. United Bank grew its stake in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after purchasing an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC grew its holdings in Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after acquiring an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board grew its stake in shares of Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after purchasing an additional 292,547 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 0.1%

Shares of NYSE ABT opened at $116.70 on Tuesday. The stock has a market cap of $201.94 billion, a PE ratio of 37.77, a P/E/G ratio of 2.26 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a 50-day moving average of $100.64 and a 200 day moving average of $100.03.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s revenue was up 13.0% on a year-over-year basis. During the same period last year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New diabetes-device opportunity: Medtronic has begun shipping its MiniMed Flex insulin pump, which uses an Abbott-made glucose sensor. The launch and accompanying marketing campaign could expand Abbott’s sensor presence in the growing diabetes-care market. MiniMed starts shipping new insulin pump with Abbott-made sensor
• Positive Sentiment: Underlying business remains diversified: Analyst commentary highlights Abbott’s established diagnostics, medical-device and nutrition franchises, along with long-term growth opportunities. Its latest reported quarter also exceeded consensus earnings and revenue estimates, with revenue up 13% year over year. Ken Griffin Just Loaded Up on AbbVie and Abbott
• Neutral Sentiment: Formula litigation clarity: Abbott agreed to pay approximately $670 million to resolve the Gill case and about 2,000 additional necrotizing-enterocolitis claims without admitting liability. The settlement is costly, but it removes uncertainty tied to a large jury award and provides greater visibility into remaining litigation exposure. How Investors Are Reacting To Abbott Laboratories US$670 Million NEC Settlement
• Neutral Sentiment: Investor comparisons are favorable but valuation-sensitive: Articles describe Abbott as a potential long-term healthcare and dividend investment, though comparisons with Envista, Intuitive Surgical, Thermo Fisher and Johnson & Johnson emphasize differing growth, recovery and valuation profiles. NVST or ABT: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Diagnostics growth is uneven: Weaker respiratory-testing demand is offsetting healthy routine testing and approximately 13% growth in cancer diagnostics. This mix could moderate near-term Diagnostics momentum despite strength in higher-growth categories. Here’s What Is Shaping Abbott’s Diagnostics Growth

Wall Street Analyst Weigh In

A number of research firms have recently commented on ABT. Citigroup boosted their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. JPMorgan Chase & Co. boosted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a report on Thursday, August 13th. Finally, Bank of America lowered their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $118.67.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.